Form 8-K - Current report:
SEC Accession No. 0001708599-25-000048
Filing Date
2025-04-29
Accepted
2025-04-29 16:33:28
Documents
17
Period of Report
2025-04-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ser-20250425.htm   iXBRL 8-K 33274
2 EX-1.1 exhibit11-sersalesagreement.htm EX-1.1 295591
3 EX-4.1 exhibit41-descriptionofsec.htm EX-4.1 9878
4 EX-5.1 bradleyopiniontoserinaatmo.htm EX-5.1 14038
8 image_0.jpg GRAPHIC 46381
  Complete submission text file 0001708599-25-000048.txt   696037

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ser-20250425.xsd EX-101.SCH 1800
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ser-20250425_lab.xml EX-101.LAB 54435
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ser-20250425_pre.xml EX-101.PRE 31811
19 EXTRACTED XBRL INSTANCE DOCUMENT ser-20250425_htm.xml XML 2820
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38519 | Film No.: 25888338
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)